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GlycA is a novel nuclear magnetic resonance spectroscopy-measured biomarker of sys-
temic inflammation. We determined whether GlycA is associated with incident cardiovascu-
lar disease (CVD) in men and women, examined whether this association with CVD is
modified by renal function, and compared this association with high sensitivity C-reactive
protein (hsCRP).
Research design and methods
A prospective cohort study was performed among 4,759 subjects (PREVEND study) with-
out a history of CVD and cancer. Incident CVD was defined as the combined endpoint of
cardiovascular morbidity and mortality. Cox regression analyses were used to examine
associations of baseline GlycA and hsCRP with CVD.
Results
298 first CVD events occurred during a median follow-up of 8.5 years. After adjustment for
clinical and lipid measures the hazard ratio (HR) for CVD risk in the highest GlycA quartile
was 1.58 (95% CI, 1.05–2.37, P for trend = 0.004). This association was similar after further
adjustment for renal function (estimated glomerular filtration rate and urinary albumin excre-
tion). After additional adjustment for hsCRP, GlycA was still associated with incident CVD
(HR: 1.16 per SD change (95% CI, 1.01–1.33), P = 0.04). Similar results were obtained for
hsCRP (HR per SD change after adjustment for GlycA: 1.17 (95% CI 1.17 (95% CI, 1.01–
3.60), P = 0.04). CVD risk was highest in subjects with simultaneously higher GlycA and
hsCRP (fully adjusted HR: 1.79 (95% CI, 1.31–2.46), P<0.001).
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Conclusion
GlycA is associated with CVD risk in men and women, independent of renal function. The
association of GlycA with incident CVD is as strong as that of hsCRP.
Introduction
It is increasingly recognized that protein glycosylation, i.e. the enzymatic process whereby a
glycan (polysaccharide) moiety is added to a protein, affects many physiological processes
including the innate immune system, thereby modulating inflammatory responses [1–3]. Cir-
culating glycosylated acute phase proteins are elevated in various inflammatory and autoim-
mune disorders [4]. It is well known that atherosclerotic cardiovascular disease (CVD) is
featured by enhanced low grade inflammation [5,6]. To date, numerous studies have shown
that higher circulating levels of acute phase proteins, in particular high sensitivity C-reactive
protein (hsCRP), predict future development of cardiovascular disease (CVD) [4,5,7,8],
although the possibility that CRP may play a causal role in derangements of inflammatory pro-
cesses involved in the pathogenesis of atherosclerosis has been questioned [9,10].
GlycA is a recently developed nuclear mass resonance (NMR) spectroscopy-derived bio-
marker of systemic inflammation [11,12]. This NMR signal arises from the N-acetyl methyl
groups of the N-acetylglucosamine residues located on specific glycan branches of circulating
plasma proteins, mainly α1-acid glycoprotein (oromucosoid), haptoglobin, α1-antitrypsin,
α1-antichymotrypsin and transferrin. It has been established that GlycA is strongly correlated
with hs-CRP, which supports the contention that GlycA is a marker of low-grade systemic
inflammation [11,13].
Interestingly, it has been recently shown that plasma GlycA is independently associated
with incident CVD in a large cohort study of initially healthy women [13]. In this report, the
association of GlycA with incident CVD was similar to that of hsCRP. Of note, the associations
of GlycA and hsCRP with incident CVD were attenuated after mutual adjustment for these
inflammatory markers, which raises the possibility that GlycA and hsCRP are biomarkers that
reflect in part common processes involved in atherosclerosis development. At present it is
unknown whether the association of GlycA with future development of clinically manifest
CVD also holds true for men. Of further importance, no data are available with respect to the
relationship of GlycA with renal function and albuminuria. It is important to determine these
relationships, because both lower estimated glomerular filtration rate (eGFR) and higher
degrees of albuminuria confer increased risk of cardiovascular morbidity and mortality [14–
16]. Moreover, low grade chronic inflammation as inferred from higher hsCRP predicts a
decline in renal function, and associates with albuminuria [14,17,18].
We therefore initiated the present study to determine i) whether GlycA associates with
increased CVD risk in both men and women, ii) the extent to which the anticipated associa-
tion of GlycA with future CVD is modified by renal function abnormalities, as inferred from
eGFR and albuminuria and iii) the extent to which the anticipated association of GlycA with
future CVD is attenuated by hsCRP, representing a widely used marker of low-grade chronic
inflammation. To this end a prospective evaluation was performed among participants of the
Prevention of Renal and Vascular ENd-Stage Disease (PREVEND) study, a prospective investi-
gation of albuminuria, renal and cardiovascular disease in a large, predominantly Caucasian
population.
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adherence to PLOS ONE policies on sharing data
and materials.
Materials and Methods
Study design and population
Details of the PREVEND study are described elsewhere [19,20]. In summary, in 1997 through
1998, all inhabitants of the city of Groningen, The Netherlands, between the ages of 28 and 75
years (85,421 subjects) were asked to send in a morning urine sample and to fill out a short
questionnaire. Pregnant women and subjects with type 1 diabetes mellitus were excluded. The
urinary albumin concentration was assessed in 40,856 responders. Subjects with a urinary albu-
min concentration10 mg/L (n = 7,768) were invited to participate, of whom 6,000 were
enrolled. In addition, a randomly selected group with a urinary albumin concentration of<10
mg/L (n = 3,394) was invited to participate in the cohort, of whom were 2,592 were enrolled.
These 8,592 individuals constitute the PREVEND cohort. The second screening took place
from 2001 through 2003 (n = 6,894), which was the starting point of the present evaluation.
The PREVEND study has been approved by the Medical Ethics Committee of the University
Medical Center Groningen, and is performed in accordance with Declaration of Helsinki
guidelines. All participants provided written informed consent. GlycA and hsCRP were mea-
sured in 5,526 subjects in whom previously unthawed samples were available. For the present
study subjects with a history of CVD (n = 349) and cancer (n = 418) at baseline were excluded,
leaving 4,759 subjects for the analysis.
Follow-up and outcome
Follow-up time was defined as the period between assessment at the second screening round
(baseline) and first CVD event, loss to follow-up, or the end of follow up time (01-01-2011),
whichever came first. If a person had moved to an unknown destination, the date on which the
person was dropped from the municipal registry was used as the census date.
Data on mortality were obtained from the municipal register, and the cause of death was
obtained by linking the number of the death certificate to the primary cause of death as coded
by a physician from the Central Bureau of Statistics. Information for cardiovascular morbidity
was obtained from PRISMANT, the Dutch national registry of hospital discharge diagnoses.
All data were coded according to
the International Classification of Diseases, the Ninth Revision (ICD-9) was used for data
until 01-01-2009, after this date, data were coded according to the Tenth Revision (ICD-10).
CVD was defined as the combined endpoint of incident cardiovascular morbidity and mortal-
ity which includes the following events: acute myocardial infarction, acute and subacute ischae-
mic heart disease, occlusion or stenosis of the precerebral or cerebral arteries or the following
procedures: coronary artery bypass grafting, percutaneous transluminal coronary angioplasty
or other vascular interventions (i.e. percutaneous transluminal angioplasty or bypass grafting
of the aorta and peripheral vessels). Cardiac events were defined as fatal ⁄nonfatal myocardial
infarction, ischemic heart disease, coronary artery bypass grafting and percutaneous translum-
inal coronary angioplasty.
Baseline measurements and definitions
Body mass index (BMI) was calculated as weight (kg) divided by height squared (meter).
Smoking status was categorized as never, former and current. Alcohol intake was categorized
as almost never, 1–4 drinks per month or 2–7 drinks per week, and1 drink per day. Blood
pressure was measured with an automatic Dinamap XL Model 9300 series device (Johnson-
Johnson Medical, Tampa, FL, USA). Hypertension was defined as a systolic blood pressure
(SBP)>140 mmHg or a diastolic blood pressure (DPB)>90 mmHg, or the use of blood
Glycoproteins and Cardiovascular Events
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pressure-lowering drugs. Type 2 diabetes mellitus (T2DM) was defined as a fasting serum glu-
cose level>7.0 mmol/L, a non-fasting plasma glucose level>11.1 mmol/L, self-report of a phy-
sician diagnosis or the use of glucose lowering drugs, retrieved from a central pharmacy
registry. eGFR was calculated using the combined creatinine cystatin C-based Chronic Kidney
Disease Epidemiology Collaboration equation from 2012 [21].
Laboratory measurements
Fasting blood samples were provided and stored at -80°C. NMR spectra were collected from
EDTA plasma samples using the Vantera
1
Clinical Analyzer [22]. The GlycA NMR signal is
derived from the N-acetyl methyl protons of N-aceylated carbohydrate side chains of serum
glycoproteins (predominantly, α1-acid glycoprotein, haptoglobin, α1-antitrypsin, α1-antichy-
motrypsin and transferrin) [11]. The GlycA NMR signal is centered at 2.00 ± 0.01 ppm in the
NMR spectra of plasma, and only N-acetylglucosamine with specific glycosidic linkage,
namely, β (1>2) or β (1>6) with a preceding mannose residue, contribute to the GlycA signal
[11].
hsCRP was measured by nephelometry with a threshold of 0.18 mg/L (BNII, Dade Behring).
Plasma glucose was measured as described [6]. Serum total cholesterol was assayed on an auto-
matic analyser type MEGA (Merck, Darmstadt, Germany) using the CHOD-PAP-method.
Triglycerides (TG) and high density lipoprotein cholesterol (HDL-C) were measured on a
Beckman Coulter AU Analyzer. Non-HDL cholesterol was calculated as the difference between
total cholesterol and HDL cholesterol. Measurement of serum creatinine was performed by an
enzymatic method on a RocheModular analyzer (Roche Diagnostics, Mannheim, Germany).
Serum cystatin C concentrations were measured by Gentian Cystatin C Immunoassay (Gentian
AS, Moss, Norway) on a Modular analyzer (Roche Diagnostics). Urinary albumin concentra-
tion was measured by nephelometry with a threshold of 2.3 mg/l, and intra- and inter-assay
coefficients of variation of 2.2% and 2.6%, respectively, (Dade Behring Diagnostic, Marburg,
Germany).
Statistical analysis
Statistical analyses were performed using statistical software SPSS version 22.0 (SPSS Inc, Chi-
cago, IL) and STATA version 13.1 (StataCorp, College Station, TX: StataCorp LP). Normally
distributed data were expressed as mean ± SD and skewed data as median [interquartile
range]. Subject characteristics and laboratory variables were calculated across sex-stratified
quartiles of GlycA. P-values across quartiles of GlycA were determined by linear regression for
continuous variables or chi-square test for categorical variables. Skewed data were normalized
by logarithmic transformation before analyses, which was the case for triglycerides, UAE and
hsCRP. Univariable linear regression analyses are presented as standardized beta with corre-
sponding P-value.
Kaplan-Meier curves with log-rank tests were used to estimate survival curves of GlycA and
hsCRP levels, either separately or joint, on CVD outcome. Cox proportional hazards regression
analyses were used to determine the risk for incident CVD events according to quartiles of
GlycA and hsCRP, as well as per 1 SD increase of GlycA and log hsCRP. The assumption of
proportional hazards for baseline predictors was investigated by inspecting the Schoenfeld
residuals. Multivariable analyses were conducted using Cox regression models including the
covariates age, sex, BMI, alcohol intake, smoking status, prevalent T2DM, use of lipid lowering
drugs, use of anti-hypertensive medication, SBP, total cholesterol, HDL cholesterol, triglycer-
ides, eGFR, and UAE. Tests of trend across quartiles were conducted by assigning the median
value for each quartile as its value and treating this as a continuous variable. Additionally, we
Glycoproteins and Cardiovascular Events
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also evaluated the association between GlycA and hsCRP and cardiac events only, reasoning
the numbers of cerebrovascular and peripheral vascular endpoints were too low to allow for a
meaningful subanalysis. Possible effect modification was explored by including the interaction
terms between GlycA or hsCRP and age or sex in the multivariable adjusted models.
The additional value of GlycA and hsCRP for CVD risk prediction was assessed by discrimi-
nation using Harrell’s C-statistic. The theoretical maximum of 1.0 indicates perfect prediction
and a value of 0.5 indicates that patients are correctly classified in 50% of subjects (no discrimi-
nation) [23].
The joint associations of GlycA and hsCRP on outcome were evaluated by dichotomizing
the distribution of GlycA and hsCRP, according to cut points of the highest quartile of GlycA
(>387 μmol/L) and the highest quartile of hsCRP (>2.95 mg/L) in both sexes combined, to
test if both biomarkers in the highest range had a different association with first CVD event vs.
both these biomarkers in the lowest range or one of these biomarkers in the lowest range.
Given the enrichment of subjects with elevated urinary albumin excretion in the PREVEND
population, we also performed a secondary analysis in which we accounted for the sampling
design of the study, with respect to enrichment of subjects with a urinary albumin concentra-
tion>10 mg/L, by specifying stratum-specific baseline hazard functions.
Interaction terms were considered to be statistically significant at two-sided P-values<0.10
[24]. Otherwise, the levels of significance was set at two-sided P-values<0.05.
Results
The baseline characteristics of the 4,759 subjects according to sex-stratified quartiles of GlycA
are presented in Table 1. The mean age of the study population was 52.7 ± 11.8 years. Subjects
in the highest quartile of GlycA were older and smoked more frequently compared to subjects
in the lowest GlycA quartile. Hypertension and T2DM were more prevalent among subjects in
the highest quartile. Levels of hsCRP, total cholesterol, non-HDL cholesterol, triglycerides and
UAE were higher, whereas HDL cholesterol and eGFR were lower in subjects in the highest
quartile vs. subjects in the lowest GlycA quartile.
The relationship between GlycA and hsCRP is shown in Fig 1. Both GlycA and hs-CRP
were higher in women than in men (Table 2). Univariable linear regression analyses showed
that age, BMI, smoking, hsCRP, glucose, total cholesterol, non-HDL cholesterol, triglycerides
and UEA were positively associated with GlycA, whereas alcohol intake, HDL cholesterol and
eGFR were inversely associated with GlycA levels (Table 2). GlycA was higher in subjects
using anti-hypertensive drugs, lipid lowering drugs and glucose lowering medication. Similar
associations were observed for hsCRP.
After a median follow-up period of 8.5 (7.9–9.0) years 298 CVD events occurred (6.3%);
210 (70.5%) of these events were cardiac. Kaplan Meier curves for GlycA and hsCRP are
shown in Fig 2. The Schoenfeld residuals did not suggest deviations from proportionality, sup-
porting the assumption of proportional hazards. Associations of GlycA and hsCRP with CVD
risk are shown in Table 3. In crude analysis, there was a robust dose response effect of GlycA
on incident CVD (P for trend<0.001). Results remained essentially similar after additional
adjustment for age and sex (model 1). Further adjustment for BMI, alcohol intake, smoking
status (model 2), as well as T2DM, SBP, lipid lowering drug, anti-hypertensive medications
(model 3) and lipid levels (model 4) did not result in any substantial change. Additional adjust-
ment for eGFR and UAE (model 5) did not alter the results. Although the association of GlycA
with incident CVD when evaluated as P for trend was no longer significant after adjustment
for hsCRP, GlycA remained independently associated with CVD when evaluated per SD
change (model 6). Results for CRP were comparable to those for GlycA. As with GlycA the
Glycoproteins and Cardiovascular Events
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association of hsCRP with incident CVD remained present taking account of eGFR and UAE
(model 5). Also, when evaluated per SD change the association of hsCRP with incident CVD
Table 1. Baseline characteristics according to sex-stratified quartiles of GlycA concentrations in 4,759 participants of the PREVEND study.
Quartiles of GlycA, μmol/L
1 2 3 4
♂301 ♂302–335 ♂336–377 ♂378 P-value
♀311 ♀312–350 ♀351–392 ♀393
Participants, n 1186 1182 1205 1186
Age, years 48.6±10.6 52.2±11.8 54.5±11.9 55.5±11.8 <0.001
Female, n (%) 641 (54.0) 642 (54.3) 657 (54.5) 641 (54.0) 0.99
BMI, kg/m2 24.6±3.4 26.1±3.7 27.2±4.1 28.3±4.9 <0.001
Smoking, n (%) <0.001
Never 480 (40.4) 376 (31.8) 316 (26.2) 287 (24.2)
Former 490 (41.3) 519 (43.9) 514 (42.7) 446 (37.6)
Current 201 (16.9) 273 (20.1) 360 (29.9) 441 (37.2)
Alcohol intake, n (%) <0.001
Almost never 222 (18.7) 243 (20.6) 321 (26.6) 363 (30.6)
1–4 drinks per month 190 (16.0) 214 (18.1) 202 (16.8) 191 (16.1)
2–7 drinks per week 454 (38.3) 391 (33.1) 363 (30.1) 323 (27.2)
1 drinks per day 310 (26.1) 321 (27.2) 309 (25.6) 299 (25.2)
Hypertension, n (%) 177 (14.9) 296 (25.0) 436 (36.2) 507 (42.7) <0.001
Lipid lowering drug use, n (%) 40 (3.4) 58 (4.9) 103 (8.5) 128 (10.8) <0.001
SBP, mmHg 118.4±15.3 123.8±18.2 127.8±19.7 130.6±18.9 <0.001
DBP, mmHg 70.2±8.6 72.4±8.8 74.0±9.0 74.7±8.7 <0.001
T2DM, n (%) 21 (1.8) 38 (3.2) 74 (61) 106 (8.9) <0.001
Blood pressure-lowering drug use, n (%) 102 (8.6) 170 (14.4) 277 (23.0) 333 (28.1) <0.001
Use of glucose-lowering drugs, n (%) 6 (0.5) 19 (1.6) 40 (3.3) 61 (5.3) <0.001
hsCRP, mg/L 0.52 [0.26–0.95] 0.98 [0.56–1.70] 1.75 [0.93–3.19] 3.61 [1.86–7.10] <0.001
Glucose, mmol/L 4.7±0.9 4.9±0.9 5.1±1.1 5.3±1.3 <0.001
Total cholesterol, mmol/L 5.2±1.0 5.4±1.0 5.6±1.0 5.7±1.1 <0.001
Non-HDL cholesterol, mmol/L 3.8±1.0 4.1±1.0 4.3±1.0 4.5±1.1 <0.001
HDL cholesterol, mmol/L 1.4±0.3 1.3±0.3 1.2±0.3 1.3±0.3 <0.001
Triglycerides, mmol/L 0.84 [0.64–1.70] 1.03 [0.78–1.97] 1.22 [0.88–1.70] 1.39 [1.02–1.86] <0.001
eGFRcrea-cysC, ml/min per 1.73 m2 98.2±13.9 93.6±16.4 90.7±16.3 88.0±18.1 <0.001
eGFRcrea-cysC, ml/min per 1.73 m2, categorical <0.001
90 ml/min per 1.73 m2 845 (71.2) 689 (58.3) 631 (52.4) 541 (45.6)
60 ml/min per 1.73 m2 276 (23.3) 383 (32.4) 450 (37.3) 471 (39.7)
<60 ml/min per 1.73 m2 7 (0.6) 24 (2.0) 43 (3.6) 75 (6.3)
UAE, mg/ 24h 7.1 [5.7–10.3] 7.6 [5.8–11.4] 8.4 [6.1–13.3] 8.9 [6.1–17.9] <0.001
UAE, mg/24H, categorical <0.001
30 40 (3.4) 80 (6.8) 109 (9.0) 186 (15.7)
<30 1141 (96.2) 1096 (92.7) 1090 (90.5) 996 (84.0)
Data are expressed as mean ± SD, median [IQR] or in number (n) and %. P-values are calculated by linear regression analysis or χ2 analysis. Data with
respect to smoking and alcohol consumption are missing in 56 (1.2%) and 43 (0.9%) of the subjects, respectively. Abbreviations: BMI, body mass index;
eGFRcrea-cysC, estimated glomerular ﬁltration rate based on creatinine-cystatin C equation; DBP, diastolic blood pressure; SBP, systolic blood pressure;
T2DM, type 2 diabetes mellitus; HDL-cholesterol, high density lipoprotein cholesterol; hsCRP; high sensitive- C-reactive protein; UAE, urinary albumin
excretion; PREVEND, Prevention of REnal and Vascular ENd-stage Disease.
doi:10.1371/journal.pone.0139057.t001
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was still significant after adjustment for GlycA (model 6). There were no statistically significant
interactions between GlycA or hsCRP and age or sex on CVD outcome [interactions: P>0.10
for all, data not shown].
When the analyses were restricted to the cardiac domain (210 events) GlycA was associated
with incident cardiac events in analyses adjusted for clinical covariates, lipids, eGFR and UAE
(S1 Table), both when evaluated as P for trend (HR 1.72 (95% CI, 1.02–2.89), P = 0.009) and as
per SD change (HR 1.23 (95% CI, 1.07–1.40), P = 0.003). In analysis in which we additionally
adjusted for hsCRP (cf. model 6, Table 3), GlycA was still associated with incident cardiac
events (HR 1.19 (95% CI, 1.01–1.42), P = 0.04), whereas the fully adjusted association of
hsCRP with cardiac events was not significant (HR 1.05 (95% CI, 0.87–1.26), P = 0.62).
The Harrell’s C-index for the Cox regression model with age and sex was 0.77 (95% CI:
0.75–0.80), indicating that 77% of the patients were correctly classified. Addition of GlycA or
hsCRP to this basic model resulted in a significant improvement in the C-statistic (0.016 (95%
CI, 0.006–0.02), P = 0.001 and 0.012 (95% CI, 0.003–0.022), P = 0.01, respectively). However,
on top of a Cox regression model which included age, sex, BMI, smoking status and alcohol
use, addition of neither GlycA, nor hsCRP resulted in a significant change in the C-statistic
(0.005 (95% CI: -0.001–0.012), P = 0.10 and 0.003 (95% CI, -0.003–0.009), P = 0.34).
We next performed a joint analysis based on dichotomized subgroups with higher and
lower GlycA or hsCRP in both sexes combined. Kaplan-Meier curves for the 4 prespecified
groups of high and low GlycA or hsCRP are shown in Fig 3. In crude as well as in age-and sex-
adjusted analysis higher GlycA (>387 μmol/L) and higher hsCRP (>2.95 mg/L) both alone
and combined were associated with increased CVD risk compared with the reference group
of subjects with lower GlycA and lower hsCRP (Table 4). After multivariable adjustment,
Fig 1. Scatter plot showing the correlation between GlycA and high sensitivity C-reactive protein (hsCRP) (univariate correlation coefficient: 0.67).
doi:10.1371/journal.pone.0139057.g001
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simultaneous occurrence of higher hsCRP and higher GlycA (GlycA> 387 μmol/L and hsCRP
>2.95 mg/L) was still associated increased CVD risk, whereas the association of either higher
GlycA or higher hsCRP with incident CVD had lost significance (Table 4).
In secondary analysis, in which we accounted for the design of the PREVEND study, the
association between GlycA and hsCRP and CVD events was still significant after adjustment
Table 2. Univariate associations of clinical parameters with GlycA and hsCRP.
GlycA hsCRP
Clinical parameter Std B P-value Std B P-value
Age 0.22 <0.001 0.25 <0.001
Sex
Males Reference Reference
Females 0.10 <0.001 0.04 <0.001
BMI, kg/m2 0.31 <0.001 0.39 <0.001
Smoking
Never Reference Reference
Former 0.06 0.001 0.08 0.001
Current 0.19 <0.001 0.12 <0.001
Alcohol intake
Almost never Reference Reference
1–4 drinks per month -0.09 <0.001 -0.07 <0.001
2–7 drinks per week -0.16 <0.001 -0.12 <0.001
1 drinks per day -0.13 <0.001 -0.09 <0.001
SBP, mmHG 0.22 <0.001 0.23 <0.001
DBP, mmHg 0.16 <0.001 0.18 <0.001
Hypertension 0.23 <0.001 0.23 <0.001
Type 2 diabetes mellitus 0.13 <0.001 0.12 <0.001
Use of blood pressure lowering drugs
No Reference Reference
Yes 0.20 <0.001 0.20 <0.001
Use of lipid lowering drugs
No Reference Reference
Yes 0.12 <0.001 0.06 <0.001
Use of glucose lowering drugs
No Reference Reference
Yes 0.12 <0.001 0.09 <0.001
hsCRP, mg/L 0.67 <0.001 - -
GlycA - 0.67 <0.001
Glucose, mmol/L 0.17 <0.001 0.17 <0.001
Total cholesterol, mmol/L 0.17 <0.001 0.13 <0.001
Non-HDL cholesterol, mmol/L 0.21 <0.001 0.17 <0.001
HDL cholesterol, mmol/L -0.13 <0.001 -0.17 <0.001
Triglycerides, mmol/L 0.26 <0.001 0.21 <0.001
eGFRcrea-cysC (ml/min per 1.73 m2) -0.23 <0.001 -0.25 <0.001
UAE, mg/24h 0.18 <0.001 0.17 <0.001
Data are presented as standardized B coefﬁcient (std B) with corresponding P-value. Abbreviations: BMI, body mass index; eGFRcrea-cysC, estimated
glomerular ﬁltration rate based on creatinine-cystatin C equation; DBP, diastolic blood pressure; SBP, systolic blood pressure; HDL-cholesterol, high
density lipoprotein cholesterol; hsCRP; high sensitive- C-reactive protein; UAE, urinary albumin excretion.
doi:10.1371/journal.pone.0139057.t002
Glycoproteins and Cardiovascular Events
PLOS ONE | DOI:10.1371/journal.pone.0139057 September 23, 2015 8 / 15
for clinical covariates, lipids and eGFR (S2 Table). Furthermore, after adjustment for hsCRP,
the association between GlycA and CVD events remained significant when analyzed per 1 SD
change (HR 1.16 (95% CI, 1.01–1.34), P = 0.04); however, the P for trend was no longer statisti-
cally significant (P for trend = 0.10). Likewise, the fully adjusted association of hsCRP with
Fig 2. Kaplan-Meier curves showing incident cardiovascular events according to GlycA, P0.001 by log-rank test (A) and high sensitivity C-
reactive protein (hsCRP), P0.001 by log-rank test (B).
doi:10.1371/journal.pone.0139057.g002
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CVD events was borderline significant when expressed per SD change (HR 1.16 (95% CI: 1.00–
1.35), P = 0.05).
Discussion
This prospective study among 4,759 men and women demonstrates that a recently developed
high throughput NMR spectroscopy-based glycoprotein biomarker, designated GlycA, is asso-
ciated with incident CVD. This association was not significantly different in men and women,
and was independent of clinical risk factors and plasma lipids. Moreover, this association was
not appreciably attenuated after further adjustment for eGFR and albuminuria. Of note, the
extent to which GlycA predicted CVD risk was comparable to that for hsCRP. When these
Table 3. Association between GlycA and hsCRP levels and cardiovascular event in 4,759 participants (298 events) of the PREVEND study.
Quartile 1 Quartile 2 P-value Quartile 3 P-value Quartile 4 P-value P for trend* Per 1 SD** P-value
GlycA
Participants (n) 1163 1213 1193 1190
Range, μmol/L <307 307–343 344–386 387
No. of cases (%) 35 (3.0) 58 (4.8) 85 (7.1) 120 (10.1)
Person years 9342 9652 9393 8988
Crude (reference) 1.60 [1.05–2.44] 0.03 2.41 [1.63–3.58] <0.001 3.56 [2.44–5.19] <0.001 <0.001 1.53 [1.39–1.67] <0.001
Multivariable model 1 (reference) 1.27 [0.83–1.94] 0.26 1.91 [1.28–2.84] 0.001 2.75 [1.88–4.04] <0.001 <0.001 1.41 [1.29–1.54] <0.001
Multivariable model 2 (reference) 1.16 [0.76–1.78] 0.50 1.60 [1.06–2.40] 0.02 2.09 [1.40–3.13] <0.001 <0.001 1.34 [1.21–1.48] <0.001
Multivariable model 3 (reference) 1.09 [0.71–1.68] 0.68 1.43 [0.95–2.15] 0.09 1.84 [1.22–2.76] 0.003 <0.001 1.28 [1.16–1.42] <0.001
Multivariable model 4 (reference) 1.02 [0.66–1.57] 0.94 1.29 [0.85–1.95] 0.23 1.58 [1.05–2.37] 0.03 0.004 1.24 [1.12–1.38] <0.001
Multivariable model 5 (reference) 1.04 [0.66–1.64] 0.88 1.41 [0.91–2.19] 0.12 1.75 [1.13–2.70] 0.01 0.001 1.27 [1.14–1.42] <0.001
Multivariable model 6 (reference) 0.94 [0.59–1.50] 0.80 1.19 [0.76–1.87] 0.45 1.31 [0.81–2.12] 0.27 0.18 1.16 [1.01–1.33] 0.04
hsCRP
Participants (n) 1187 1190 1191 1191
Range, mg/L <0.60 0.60–1.30 1.31–2.94 2.95
No. of cases (%) 37 (3.1) 54 (4.5) 83 (7.0) 124 (10.4)
Person years 9507 9485 9333 9050
Crude (reference) 1.46 [0.96–2.22] 0.08 2.28 [1.55–3.36] <0.001 3.52 [2.44–5.08] <0.001 <0.001 1.65 [1.48–1.84] <0.001
Multivariable model 1 (reference) 1.05 [0.69–1.60] 0.82 1.43 [0.96–2.11] 0.08 2.22 [1.53–3.23] <0.001 <0.001 1.47 [1.31–1.66] <0.001
Multivariable model 2 (reference) 0.96 [0.63–1.48] 0.87 1.13 [0.75–1.71] 0.55 1.69 [1.13–2.51] 0.01 <0.001 1.36 [1.19–1.54] <0.001
Multivariable model 3 (reference) 0.91 [0.59–1.40] 0.67 1.06 [0.70–1.60] 0.79 1.53 [1.02–2.28] 0.04 0.001 1.33 [1.16–1.51] <0.001
Multivariable model 4 (reference) 0.84 [0.55–1.29] 0.43 0.95 [0.63–1.44] 0.82 1.34 [0.89–2.01] 0.16 0.003 1.28 [1.12–1.47] <0.001
Multivariable model 5 (reference) 0.93 [0.59–1.47] 0.75 1.11 [0.71–1.72] 0.66 1.55 [1.01–2.40] 0.05 0.001 1.34 [1.16–1.54] <0.001
Multivariable model 6 (reference) 0.87 [0.55–1.37] 0.87 0.97 [0.62–1.51] 0.88 1.19 [0.75–1.90] 0.46 0.10 1.20 [1.01–1.43] 0.04
Hazard ratios were derived from Cox proportional hazards regression models.
Multivariable model 1: crude model + age, sex
Multivariable model 2: model 1 + BMI, alcohol intake, smoking status
Multivariable model 3: model 2 + type 2 diabetes mellitus, systolic blood pressure, lipid lowering drugs and anti-hypertensive medications
Multivariable model 4: model 3 + total cholesterol, HDL cholesterol, triglycerides.
Multivariable model 5: model 4 + eGFRcrea-cystatin C, UAE
Multivariable model 6: model 5 + hsCRP (for GlycA analyses) + GlycA (for hsCRP analyses).
Triglycerides, UAE and hsCRP were log transformed when used as a continuous variable in the analyses.
*Tests of trend across increasing quartiles were conducted by assigning the median for each quartile as its value and treating this as a continuous
variable.
** 1 SD is 60.4 μmol/L for GlycA and 1.1 mg/L for hsCRP (hsCRP was natural log transformed). Abbreviations: BMI, body mass index; eGFRcrea-cysC,
estimated glomerular ﬁltration rate based on creatinine-cystatin C equation; HDL-cholesterol, high density lipoprotein cholesterol; hsCRP, high-sensitivity
C-reactive protein; UAE, urinary albumin excretion.
doi:10.1371/journal.pone.0139057.t003
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pro-inflammatory biomarkers were included together in the analyses, their associations with
incident CVD were attenuated. Furthermore, CVD risk was highest in subjects with simulta-
neously higher GlycA and hsCRP, which suggests that these biomarkers may have additive
potential in predicting CVD risk. Taken together, the present findings underscore the proposed
role of altered protein glycan dynamics in inflammatory processes that may conceivably play a
role in the development of atherosclerotic CVD.
hsCRP is a single biomarker of low-grade systemic inflammation. In contrast, the GlycA
assay represents an NMR signal derived from residues within the carbohydrate side-chains of
several of the most important acute-phase proteins [11,12,25]. It should be noted that the
GlycA assay is not designed for determination of the relative contributions of the individually
captured glycosylated protein moieties to the NMR signal. Interesting though, one of the acute
phase proteins included in the NMR signal is α1-acid glycoprotein, which has been shown to
Fig 3. Kaplan-Meier curves of incident cardiovascular events according to joint levels of higher GlycA and hsCRP, P0.001 by log-rank test.
Higher levels of GlycA and hsCRP were defined as >387 μmol/L for GlycA and >2.95 mg/L for hsCR in both sexes combined. hsCRP, high sensitivity C-
reactive protein.
doi:10.1371/journal.pone.0139057.g003
Table 4. Associations of joint GlycA and hsCRP levels and cardiovascular events in 4,759 participants (298 events) of the PREVEND study.
Low GlycA and low
hsCRP












Participants (n) 3079 503 479 688
No. of cases
(%)
135 (4.4) 45 (8.9) 39 (8.1) 79 (11.5)
Crude (reference) 2.09 [1.49–2.93] <0.001 1.93 [1.35–2.75] <0.001 2.81 [2.13–3.71] <0.001
Model 1 (reference) 1.64 [1.17–2.30] 0.004 1.68 [1.18–2.40] 0.004 2.41 [1.82–3.20] <0.001
Model 2 (reference) 1.38 [0.96–1.98] 0.08 1.27 [0.87–1.85] 0.22 1.79 [1.31–2.46] <0.001
Higher levels were deﬁned as greater than the upper quartile, GlycA >387 μmol/L and hsCRP >2.95 mg/L.
Multivariable model 1: Crude + age, sex.
Multivariable model 2: Model 1 + BMI, alcohol intake, smoking status, diabetes mellitus type 2, lipid lowering drugs, anti-hypertensive medications and
systolic blood pressure, total cholesterol, HDL cholesterol, triglycerides, eGFRcrea-cysC and UAE.
Triglycerides, UAE and hsCRP were log transformed when used as a continuous variable in the analyses.
Abbreviations: BMI, body mass index; HDL-cholesterol, high density lipoprotein cholesterol; eGFRcrea-cysC, estimated glomerular ﬁltration rate based on
creatinine-cystatin C equation; hsCRP, high-sensitivity C-reactive protein; UAE, urinary albumin excretion.
doi:10.1371/journal.pone.0139057.t004
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be an independent predictor of cardiovascular morbidity and mortality in other large cohorts
[26,27]. A potential advantage of the GlycA measurement is that its level is less variable than
that of hsCRP [11]. Glycan structures of acute-phase proteins are modified under chronic
inflammatory conditions [1,11]. The robust positive correlation of GlycA with hsCRP, as rein-
forced here, supports the contention that this glycoprotein biomarker reflects a pro-inflamma-
tory state [11,12]. The positive relationships between GlycA and CVD risk factors, such as
obesity, smoking, hypertension as well as total cholesterol, non-HDL cholesterol and triglycer-
ides, and its inverse correlation with HDL cholesterol are in full agreement with recent reports
[11,13,28]. Moreover, GlycA was higher in T2DM subjects, although it appears that the extent
to which GlycA varies according to glucose tolerance status is modest [28]. Very similar rela-
tionships of these variables were found for hsCRP. The proposed pathogenic role of low-grade
systemic inflammation in renal function loss, and the association of hsCRP with albuminuria
[17,18,29–32] led us to determine the relationships of GlycA with eGFR and albuminuria. Of
further relevance, acute-phase proteins, such as α1-acid glycoprotein and α1-antitrypsin which
are captured by the GlycA assay, are present in human urine [33,34]. α1-Acid glycoprotein is
correlated with albuminuria, and its urinary excretion is increased in diabetic nephropathy
[34]. In hemodialysis patients, circulating levels of α1-acid glycoprotein are inversely associ-
ated with serum albumin, which in turn may predicts mortality [35]. A potentially relevant
novel finding of our study is that GlycA, like hsCRP, was inversely associated with eGFR and
positively with albuminuria. Given the relevance of even mild degrees of chronic kidney disease
and albuminuria for the development of atherosclerotic CVD [14,15] and the presently
observed relationship of GlycA with renal function abnormalities, it is remarkable that the
association of GlycA with incident CVD was not attenuated after adjustment for eGFR and
albuminuria. This observation raises the possibility that the impact of alterations in glycopro-
tein metabolism and of renal functional changes on CVDmay at least in part be attributable to
distinct biological pathways.
It is evident that our central finding that GlycA predicts incident CVD independent of clini-
cal and laboratory covariates agrees with recent results from the Women’s Health Study [13].
We were also able to demonstrate that GlycA improved CVD risk classification when added to
a simple model including age and sex. However, the extent to which adding GlycA improved
CVD risk classification did not reach significance in analysis taking account of established
CVD risk factors. Thus, it is anticipated that results from additional case-cohort studies are
required to more robustly discern whether GlycA may independently improve prediction of
new onset CVD.
Several methodological aspects of our study should be addressed. We consider the compre-
hensive assessment of laboratory variables, including lipoprotein fractions, eGFR and albumin-
uria in a large population of men and women a strength of our study. Second, as in previous
reports [6,13,36,37], we only included subjects without clinically manifest cardiovascular dis-
ease at baseline. Thus the association of GlycA with recurrent CVD remains to be established.
Third, the PREVEND study population consists of almost only Caucasians. Therefore, the
applicability of the current results to other ethnicities remains uncertain. Fourth, subjects with
elevated urinary albumin excretion are overrepresented in the PREVEND cohort. Of note, the
association of GlycA with incident CVD remained present after adjustment for eGFR and albu-
minuria, and a secondary analysis taking account of the design of the PREVEND study showed
similar results. Nonetheless, we cannot completely rule out the possibility of residual con-
founding. Finally, it should be emphasized that the process of glycosylation should be dis-
cerned from protein glycation, whereby a sugar molecule is covalently bound to a protein via a
non-enzymatic mechanism.
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In conclusion, this prospective cohort study involving both men and women demonstrates
that GlycA, a new pro-inflammatory glycoprotein biomarker is associated with future CVD
events, independent of clinical and laboratory variables including renal function. The associa-
tion of GlycA with incident CVD is as strong as that of hsCRP. CVD risk was highest in the
context of simultaneously higher GlycA and hsCRP, suggesting that these biomarkers may
have additive potential in predicting CVD.
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